Aptevo Therapeutics (APVO) Operating Income (2015 - 2026)
Aptevo Therapeutics (APVO) posted Operating Income of -$6.8 million for Q1 2026, down 14.03% sequentially from -$6.0 million in Q4 2025, and down 5.51% YoY from -$7.2 million in Q1 2025.
Aptevo Therapeutics (APVO) Operating Income (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Operating Income for 12 years, with the latest figure at -$6.8 million in Q1 2026.
- Quarterly Operating Income fell 5.51% year-over-year to -$6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.7 million (down 10.66% YoY) and the FY2025 annual result came in at -$26.3 million, down 6.95% from the prior year.
- Operating Income eased to -$6.8 million in Q1 2026 per APVO's latest filing, from -$6.0 million in the prior quarter.
- Over five years, Operating Income peaked at -$5.2 million in Q3 2024 and troughed at -$8.2 million in Q2 2023.
- A 5-year average of -$6.8 million and a median of -$6.6 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2024: Operating Income sank 90.2% in 2022, then advanced 26.34% in 2024.
- Over 5 years, Operating Income stood at -$7.7 million in 2022, then rose by 16.92% to -$6.4 million in 2023, then increased by 0.03% to -$6.4 million in 2024, then advanced by 6.05% to -$6.0 million in 2025, then slipped by 14.03% to -$6.8 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$6.8 million, -$6.0 million, and -$7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Aptevo Therapeutics | 3.30 Mn | -6.50 Mn | - | -6.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.44 Mn |
| Mar 31, 2026 | -6.84 Mn |
| Dec 31, 2025 | -6.00 Mn |
| Sep 30, 2025 | -7.61 Mn |
| Jun 30, 2025 | -6.23 Mn |
| Mar 31, 2025 | -6.48 Mn |
| Dec 31, 2024 | -6.38 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Jun 30, 2024 | -6.02 Mn |
| Mar 31, 2024 | -6.98 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -6.56 Mn |
| Jun 30, 2023 | -8.18 Mn |
| Mar 31, 2023 | -7.76 Mn |
| Dec 31, 2022 | -7.68 Mn |
| Sep 30, 2022 | -7.78 Mn |
| Jun 30, 2022 | -7.56 Mn |
| Mar 31, 2022 | -5.61 Mn |
| Dec 31, 2021 | -4.04 Mn |
| Sep 30, 2021 | -4.75 Mn |